The biological evaluations include in vitro binding studies to assess the affinity (Kd) of these compounds for PSMA and in vivo biodistribution studies with PSMA-positive tumor mouse models to determine tumor targeting and differences in pharmacokinetics and metabolism. The gene discussed is FOLH1; the disease is neoplasm.